Greater Houston Retina Research   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Houston TX United States (1988)

Organization Overview

First Clinical Trial
2005
NCT00406471
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Amy C Schefler, MD | Charles C Wykoff, PhD, MD | Greater Houston Retina Research

Active Ingredients

Drugs in Phase 4 Trials (2)

aflibercept (zaltrap) (6 trials)

ranibizumab (lucentis) (8 trials)

Drugs in Phase 3 Trials (1)

pegaptanib (macugen) (1 trial)

Drugs in Phase 2 Trials (1)

faricimab (Vabysmo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 3)

Edema (Phase 2)

Eye Diseases (Phase 1)

Ischemia (Phase 1)

Macular Degeneration (Phase 4)

Macular Edema (Phase 4)

Pathologic Processes (Phase 1)

Retinal Detachment (Phase 3)

Retinal Diseases (Phase 3)

Retinal Vein Occlusion (Phase 4)

Vitreous Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 4